Therapeutic vaccination with tumor cells that engage CD137

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of molecular medicine

• Publication date

  2003-02-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00109-002-0413-8PMID 12601523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?

  2007cited by this paper
• Exploiting dendritic cells to improve vaccine efficacy.

  2002cited by this paper
• Dendritic and Natural Killer Cells Cooperate in the Control/Switch of Innate Immunity

  2002cited by this paper
• Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

  2002cited by this paper
• Roles of heat-shock proteins in innate and adaptive immunity

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma

  2002cited by this paper
• Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1

  2002cited by this paper
• Advances in management of high-risk gestational trophoblastic tumors.

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Chemotherapy for trophoblastic disease: current standards

  2002cited by this paper
• Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

  2002cited by this paper
• Contact-dependent Stimulation and Inhibition of Dendritic Cells by Natural Killer Cells

  2002cited by this paper
• A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

  2002cited by this paper
• Dendritic Cells Transduced with Protein Antigens Induce Cytotoxic Lymphocytes and Elicit Antitumor Immunity1

  2002cited by this paper
• Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

  2002cited by this paper
• Use of proteomic patterns in serum to identify ovarian cancer.

  2002cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells

  2002cited by this paper
• Global control of hepatitis B virus infection.

  2002cited by this paper
• Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.

  2002cited by this paper
• Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB

  2002influential reference
• Immune-Mediated Eradication of Tumors through the Blockade of Transforming Growth Factor-beta Signaling in T Cells

  2002cited by this paper
• Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.

  2002cited by this paper
• Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance

  2002cited by this paper
• An overview of the MAGE gene family with the identification of all human members of the family.

  2001cited by this paper
• Tumor Cells Express FcγRl Which Contributes to Tumor Cell Growth and a Metastatic Phenotype

  2001cited by this paper
• 4-1BB Ligand Induces Cell Division, Sustains Survival, and Enhances Effector Function of CD4 and CD8 T Cells with Similar Efficacy1

  2001cited by this paper
• Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients1

  2001cited by this paper
• Active immunization against cancer with dendritic cells: The near future

  2001cited by this paper
• Tumor cells express FcgammaRI which contributes to tumor cell growth and a metastatic phenotype.

  2001cited by this paper
• Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.

  2001cited by this paper
• MAGE‐A4, a germ cell specific marker, is expressed differentially in testicular tumors

  2001cited by this paper
• Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue.

  2001cited by this paper
• Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells

  2001cited by this paper
• CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer

  2001cited by this paper
• 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.

  2001cited by this paper
• Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity

  2001cited by this paper
• Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

  2001cited by this paper
• Danger signals: SOS to the immune system.

  2001cited by this paper
• Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.

  2001cited by this paper
• Cell Contact–Dependent Immunosuppression by Cd4+Cd25+Regulatory T Cells Is Mediated by Cell Surface–Bound Transforming Growth Factor β

  2001cited by this paper
• CD40 ligation for immunotherapy of solid tumours.

  2001cited by this paper
• Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

  2001influential reference
• Progress in human tumour immunology and immunotherapy

  2001influential reference
• Immune complexes (IC) down‐regulate the basal and interferon‐γ‐induced expression of MHC Class II on human monocytes

  2001cited by this paper
• B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo

  2001cited by this paper
• Progressive Depletion of Peripheral B Lymphocytes in 4-1BB (CD137) Ligand/I-Eα-Transgenic Mice1

  2001cited by this paper
• A Humanized Anti–4-1BB Monoclonal Antibody Suppresses Antigen-Induced Humoral Immune Response in Nonhuman Primates

  2000cited by this paper
• Identification of cancer antigens: impact on development of cancer immunotherapies.

  2000cited by this paper
• Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

  2000cited by this paper
• Dendritic Cells Genetically Engineered to Express Fas Ligand Induce Donor-Specific Hyporesponsiveness and Prolong Allograft Survival1

  2000cited by this paper
• Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas.

  2000cited by this paper
• The identification of cancer antigens: impact on the development of cancer vaccines.

  2000cited by this paper
• Antigen-processing machinery breakdown and tumor growth.

  2000influential reference
• Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells1

  2000influential reference
• High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer.

  2000cited by this paper
• Therapeutic vaccination for cancer.

  2000cited by this paper
• TAP expression provides a general method for improving the recognition of malignant cells in vivo

  2000cited by this paper
• Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation.

  2000cited by this paper
• Dendritic cell vaccination for cancer therapy

  2000cited by this paper
• CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes.

  2000cited by this paper
• Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation.

  2000influential reference
• Relationship between Fas‐ligand expression on carcinoma cell and cytotoxic T‐lymphocyte response in lymphoepithelioma‐like cancer of the stomach

  1999cited by this paper
• Papillomaviruses in human cancers

  1999cited by this paper
• CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

  1999cited by this paper
• Antiangiogenic gene therapy

  1999cited by this paper
• CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

  1999cited by this paper
• Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

  1999cited by this paper
• Fas Antigen (CD95) in pure erythroid cell line AS-E2 is induced by interferon-γ and tumor necrosis factor-α and potentiates apoptotic death

  1999cited by this paper
• Fas antigen (CD95) in pure erythroid cell line AS-E2 is induced by interferon-gamma and tumor necrosis factor-alpha and potentiates apoptotic death.

  1999cited by this paper
• Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

  1999cited by this paper
• Expression of MAGE genes in testicular germ cell tumors.

  1999cited by this paper
• Identification of CD137 as a potent monocyte survival factor

  1999cited by this paper
• T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer.

  1999cited by this paper
• Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal.

  1999cited by this paper
• Anti–4-1bb Monoclonal Antibodies Abrogate T Cell–Dependent Humoral Immune Responses in Vivo through the Induction of Helper T Cell Anergy

  1999cited by this paper
• Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

  1999cited by this paper
• Tumor-induced immune dysfunction

  1999cited by this paper
• The TRAIL to selective tumor death

  1999cited by this paper
• Tumor vaccines--a reality at last?

  1998cited by this paper
• A Novel Role for TGF-β and IL-10 in the Induction of Immune Privilege

  1998cited by this paper
• Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling.

  1998cited by this paper
• Advanced testicular cancer: update for urologists.

  1998cited by this paper
• The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.

  1998cited by this paper
• Characterization of human colon cancer antigens recognized by autologous antibodies

  1998cited by this paper
• Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines.

  1998influential reference
• Surrogate Antigen Processing Mediated by TAP-dependent Antigenic Peptide Secretion

  1998cited by this paper
• CD40 and CD154 in cell-mediated immunity.

  1998cited by this paper
• Amplification of tumor immunity by gene transfer of the co‐stimulatory 4‐1BB ligand: synergy with the CD28 co‐stimulatory pathway

  1998influential reference
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Antiangiogenic gene therapy.

  1998cited by this paper
• New Paths in Human Cancer Serology

  1998cited by this paper
• NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

  1998cited by this paper
• A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers

  1998cited by this paper
• Engagement of Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Induces Transforming Growth Factor β (TGF-β) Production by Murine CD4+ T Cells

  1998influential reference
• A novel role for TGF-beta and IL-10 in the induction of immune privilege.

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.

  1998cited by this paper
• Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo.

  1998cited by this paper

• Combining anti-checkpoint immunotherapies and cancer vaccines as a novel strategy in oncological therapy: A review.

  2024cites this paper
• ON THE ETYMOLOGY AND HISTORY OF CZECH AND ENGLISH NURSING TERMINOLOGIES

  2022cites this paper
• Spontaneous regression of metastatic cancer cells in the lymph node: a case report

  2014cites this paper
• CD137 Enhancement of HPV Positive Head and Neck Squamous Cell Carcinoma Tumor Clearance

  2014cites this paper
• Recombinant human CD137L for cancer immunotherapy: effects of different fusions and linkers on its activity

  2012cites this paper
• 4-1BB Signaling Breaks the Tolerance of Maternal CD8+ T Cells That Are Reactive with Alloantigens

  2012cites this paper
• Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.

  2010cites this paper
• Preclinical Evaluation of Concurrent Medicinal Mushroom-Based Immune-Enhancement Supplementation in Dogs Undergoing Chemotherapy for Various Cancers

  2009cites this paper
• Natural History of Cancer

  2009cites this paper
• Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.

  2009cites this paper
• Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.

  2009cites this paper
• codelivery of threshold amounts of plasmid-encoded helper antigen mediated − Enhancement of DNA tumor vaccine efficacy by gene gun

  2008cites this paper
• Cancer gene therapy of adenovirus-mediated anti-4-1BB scFv in immunocompetent mice

  2008cites this paper
• Membrane‐tethered proteins for basic research, imaging, and therapy

  2008cites this paper
• General Principles of Tumor Immunotherapy

  2007cites this paper
• B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

  2007cites this paper
• Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.

  2007cites this paper
• Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site.

  2007cites this paper
• Immunomodulatory Molecules of the Immune System

  2007cites this paper
• Immunotherapy Targeting 4-1BB and Its Ligand

  2006cites this paper
• Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv–expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion

  2006cites this paper
• Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.

  2006cites this paper
• Complete Regression of Large Solid Tumors Using Engineered Drug-Resistant Hematopoietic Cells and Anti-CD137 Immunotherapy

  2006cites this paper
• Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.

  2006cites this paper
• CD137 Signal in the Regulation of Innate Immunity

  2006cites this paper
• Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1.

  2005cites this paper
• Compositions et techniques induisant une immunite antitumorale

  2005cites this paper
• Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.

  2005cites this paper
• The therapeutic potential of 4-1BB (CD137) in cancer.

  2005cites this paper
• Murine CD8 lymphocyte expansion in vitro by artificial antigen‐presenting cells expressing CD137L (4‐1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour‐reactive effector cells in vivo

  2004cites this paper
• [Modification of glycoconjugates during the carcinogenesis: the case of mammary carcinomas].

  2004cites this paper
• Role of 4-1BB:4-1BB ligand in cancer immunotherapy

  2004cites this paper
• Vacunas en melanoma

  2004cites this paper
• Using antibodies in tumour immunotherapy

  2004cites this paper
• Immunotherapy of glioblastoma multiforme

  2003cites this paper
• Novel approaches to therapeutic cancer vaccines

  2003cites this paper